A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Exclusion Criteria

• •1. Any previous CLL specific treatment.
• •2. Failure to fully recover adequately from prior surgical procedures at the discretion of the investigator. Patients who receive a major surgery within 28 days prior to the first dose of the study drug or who receive a minor surgery (excluding biopsy) within 14 days prior to the initiation of the study.
• •3. Presence of significant cardiovascular disease within 6 months prior to study entry.
• •4. A history of significant kidney, neurological, psychiatric, pulmonary, endocrine, metabolic, immune, cardiovascular, or liver disease, which will have an adverse effect on the patient if he/she participates in the study, at the discretion of the investigator.
• •5. Patients who require warfarin or other anticoagulants or active hemorrhage occur within 2 months before study entry.
• •6. Known to have hypersensitivity to the drug ingredient or its analogues.
• •7. Pregnant or lactating female patients and patients who are expected to become pregnant during the study period or within 3 months after the last dose.
• •8. Patients who have history of other active malignant tumor other than CLL/SLL within 3 years before study entry.
• •9. With a malabsorption syndrome or other conditions unsuitable for enteral administration.
• •10. Other clinically significant uncontrolled symptoms.
• •11. With primary active autoimmune disease and connective tissue disease.
• •12. Any other circumstances or conditions that would, at the discretion of the investigator, make the patient unsuitable for the study.